Investigational drug · Phase 3
zoldonrasib
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "zoldonrasib"
First trial start
2026
Jan 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "zoldonrasib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenocarcinoma
- Pancreatic Adenosquamous Carcinoma
- NSCLC
- Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "zoldonrasib" as an intervention, largest first.
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )Pivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07621718 · 670 participants (planned) · Start May 22, 2026 · Primary completion Dec 30, 2028
Drug: Zoldonrasib; Placebo and 6 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Tucson, Arizona; New Haven, Connecticut · 25 sites in all
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07777822 · 430 participants (planned) · Start Aug 14, 2026 · Primary completion Oct 2029
Drug: zoldonrasib; Placebo and 2 more · For: NSCLC; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer NSCLC and 4 more
Sites: Anchorage, Alaska; Fort Lauderdale, Florida; Plantation, Florida · 4 sites in all
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07805954 · 400 participants (planned) · Start Aug 28, 2026 · Primary completion Mar 2029
Drug: daraxonrasib; gemcitabine and 2 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Jacksonville, Florida · 6 sites in all
Revolution Medicines, Inc.Industry
NCT07397338 · 370 participants (planned) · Start Jan 30, 2026 · Primary completion May 2029
Drug: Daraxonrasib; Elironrasib and 6 more · For: Advanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC) and 3 more
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.
Khan HY, Al Hallak MN, Aboukameel A, et al. · Cancer Lett 2026
- Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Facchinetti F, Friboulet L, Liao L, et al. · Ann Oncol 2026
- KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.
Abdelhakeem A, Ganatra N, Gul K, et al. · J Hematol Oncol 2026
- PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors.
Gani M, Agostini F, Secco L, et al. · Cell Rep 2026
- Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.
Stickler S, Eggerstorfer MT, Rieche M, et al. · Transl Lung Cancer Res 2026
- Targeting KRAS-Mutant Lung Cancers.
Garbo E, Scaparone P, Hoe HJ, et al. · J Natl Compr Canc Netw 2026
Also in development for Pancreatic Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.